Cannabidiol dominates the global drug-free cannabinoid market

The market share of therapeutically active cannabis grown for CBD fell from 96% in 2019 to 80% in 2020. In 2019, 19% of cannabis grown for drug-free cannabinoids was destined for CBG, in 2020 this number rose to 43 %. The cannabis grown for CBN production remained largely unchanged from 2019 to 2020, accounting for about 10% and 12% of the market, respectively. About 3% of growers grew the plant to produce delta-8 THC.

For several years in a row, experts and the general public in the global market for therapeutically active elements in cannabis have been discussing the possibilities of using various constituents of the plant that have enormous potential for healing / healing. Despite the fact that the overwhelming majority of commodity items currently use cannabidiol (CBD) in their products, there is an increasing activity among the producers and processors of the hemp plant in the use of the so-called “new cannabinoids” in the formulations of the created goods - cannabigerol, cannabinol, cannabichromen , cannabivarin, etc.

While CBD is still the most profitable cannabinoid in the global cannabis market, the “shift” in growers' interest in using “new cannabinoids” is likely due to research on their properties, gradually generated by demand through constantly published materials in various media, as well as the search something new and exclusive, attracting the attention of consumers. 

Which cannabinoids were grown in 2020

American consulting companies conducting research on the North American market claim that the share of therapeutically active cannabidiol grown on the market has dropped from 96% in 2019 to 80% in 2020. The interest of cannabis products and market consumers in cannabigerol (CBG) is skyrocketing. ... In particular, in 2019, 19% of cannabis grown for the extraction of drug-free cannabinoids was intended for obtaining precisely CBG; in 2020, that number rose to 43%.

Cannabinol (CBN) cannabis has remained largely unchanged from 2019 to 2020, accounting for about 10% and 12% of the market, respectively. About 3% of growers have grown the plant to produce delta-8 tetrahydrocannabinol, a category of cannabinoids that has been rapidly gaining traction over the past year. Cannabis processors exploit the overproduction of therapeutically active "green mass" of plants to buy flowers from the market in order to produce Delta-8 THC extract, an edible and smoking product that is becoming extremely popular among consumers.

Commentary of the specialists of the Association "Ukrainian technical hemp" 

Several presentations are devoted to the situation both on the global and on the national market of drug-free cannabinoids, which are prepared for the listeners of the 6th training stream of “Hemp University” , which will be demonstrated during the round table “ Problems and prospects of using therapeutically active elements of cannabis as a basis for nutraceuticals , medicinal cosmetics, animal feed or other products with medicinal properties of the plant . "